Center-Authored Papers

Filters: First Letter Of Keyword is P  [Clear All Filters]
A B C D E F G H I J K L M N O [P] Q R S T U V W X Y Z   [Show ALL]
Pyrrolidines
LaCroix AZ, Powles T, Osborne KC, Wolter K, Thompson JR, Thompson DD, Allred CD, Armstrong R, Cummings SR, Eastell R et al..  2010.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.. Journal of the National Cancer Institute. 102(22):1706-15. Abstract
Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J et al..  2010.  Lasofoxifene in postmenopausal women with osteoporosis.. The New England journal of medicine. 362(8):686-96. Abstract
LaCroix AZ, Powles T, Osborne KC, Wolter K, Thompson JR, Thompson DD, Allred CD, Armstrong R, Cummings SR, Eastell R et al..  2010.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.. Journal of the National Cancer Institute. 102(22):1706-15. Abstract
Ensrud K, LaCroix AZ, Thompson JR, Thompson DD, Eastell R, Reid DM, Vukicevic S, Cauley J, Barrett-Connor E, Armstrong R et al..  2010.  Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.. Circulation. 122(17):1716-24. Abstract
Pyrroles
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG.  2010.  Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(21):5260-8. Abstract
Hartwell LH, MAGASANIK B.  1964.  THE MECHANISM OF HISTIDASE INDUCTION AND FORMATION IN BACILLUS SUBTILIS.. Journal of molecular biology. 10:105-19.
Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ.  2008.  An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.. PharmacoEconomics. 26(4):329-39. Abstract
Hansen RN, Hackshaw MD, Sullivan SD, Ramsey SD.  2015.  The Authors Respond.. Journal of managed care & specialty pharmacy. 21(9):844.
Pyrophosphatases
Fishburn J, Hahn S.  2012.  Architecture of the yeast RNA polymerase II open complex and regulation of activity by TFIIF.. Molecular and cellular biology. 32(1):25. Abstract
Pyrimidines
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F et al..  2013.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.. Blood. 122(6):872-84. Abstract
Müller MC, Cortes JE, Kim D-W, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L et al..  2009.  Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.. Blood. 114(24):4944-53. Abstract
Somlo G, Atzori F, Strauss LC, Geese WJ, Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT, Cortes J.  2013.  Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(7):1884-93. Abstract
Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP et al..  2011.  SHP1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.. Blood. 118(13):3634-44. Abstract
Hansen RN, Hackshaw MD, Sullivan SD, Ramsey SD.  2015.  The Authors Respond.. Journal of managed care & specialty pharmacy. 21(9):844.
Woodahl EL, Wang J, Heimfeld S, Ren AG, McCune JS.  2008.  Imatinib inhibition of fludarabine uptake in T-lymphocytes.. Cancer chemotherapy and pharmacology. 62(4):735-9. Abstract
Hartwell LH.  1970.  Biochemical genetics of yeast.. Annual review of genetics. 4:373-96.
Travi G, Pergam SA, Xie H, Carpenter PA, Kiem H-P, Corey L, Boeckh MJ.  2009.  The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 49(11):e120-3. Abstract
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Turtle CJ, Hay KA, Hanafi L-A, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S et al..  2017.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(26):3010-3020. Abstract
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP et al..  2008.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.. Blood. 112(8):3500-7. Abstract
Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC et al..  2011.  Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.. Urology. 77(5):1166-71. Abstract
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond KA, Bramwell VHC, Baker LH, Maki RG et al..  2008.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(4):626-32. Abstract
Radich JP.  2010.  Stem cell transplant for chronic myeloid leukemia in the imatinib era.. Seminars in hematology. 47(4):354-61. Abstract
Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey AE, Flowers MED, Maris MB, Laport GG, Chauncey TR, Lange T et al..  2011.  Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.. Haematologica. 96(8):1113-20. Abstract